Rekombinanter KRT17 Antikörper

Produktnummer ABIN7881374

Der Kaninchen Monoklonal anti-KRT17 Antikörper (Klon KRT17-8320R) (ABIN7881374) detektiert spezifisch KRT17 in IHC (p). Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für Rekombinanter KRT17 Antikörper (ABIN7881374)

Target: KRT17 (Keratin 17 (KRT17))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser KRT17 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Güteklasse: Carrier-free

Klon: KRT17-8320R

Produktdetails anti-KRT17 Antikörper

Verwendungszweck: Recombinant Cytokeratin 17 Antibody / KRT17 (azide and preservative free)

Aufreinigung: Protein A/G affinity

Immunogen: A recombinant fragment of the human protein was used as the immunogen for the recombinant Cytokeratin 17 antibody.

Isotyp: IgG, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the recombinant Cytokeratin 17 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot the recombinant Cytokeratin 17 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Details zu KRT17

Target: KRT17 (Keratin 17 (KRT17))

Andere Bezeichnung: Cytokeratin 17

Hintergrund: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands, such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. Additionally, anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

UniProt: Q04695